| Title: | Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease |
| Lead Institution: | West China Hospital of Sichuan University |
| Principal investigator: |
Application 112111
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly defined condition encompassing hepatic steatosis and metabolic dysfunction. However, the relationship between MAFLD and multisystem diseases remains unclear, and the time-dependent sequence of these diseases requires further clarification. Therefore, using disease trajectory analysis will identified a range of increased risks of medical conditions and causes of death for individuals with MAFLD. Developing relevant intervention measures that target these key pathways may benefit the MAFLD population by preventing a decline in general health.4 Publications
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 13185 | Accelerated biological aging: unveiling the path to cardiometabolic multimorbidity, dementia, and mortality | Yi He (+7) | 2024 | Frontiers in Public Health |
| 9261 | Association between metabolic dysfunction-associated fatty liver disease and abdominal aortic aneurysm | Yu Jia (+9) | 2023 | Nutrition Metabolism and Cardiovascular Diseases |
| 13111 | Independent and joint relationships of cardiorespiratory fitness and body mass index with liver fat content | Yu Jia (+7) | 2024 | Diabetes Obesity and Metabolism |
| 13522 | Sleep patterns, genetic susceptibility, and venous thromboembolism: A prospective study of 384,758 UK Biobank participants. | Jiaxin Bai (+12) | 2024 | PLOS ONE |
Enabling scientific discoveries that improve human health